This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hagan, M. Articles by Dent, P. Search for Related Content PubMed PubMed Citation Articles by Hagan, M. Articles by Dent, P.

Ionizing Radiation Causes a Dose-Dependent Release of Transforming Growth Factor In vitro from Irradiated Xenografts and during Palliative Treatment of Hormone-Refractory Prostate Carcinoma

Departments of ¹ Radiation Oncology and ² Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia

ABSTRACT

Purpose: Characterize the radiation response for transforming growth factor (TGF) shedding in vitro and in vivo. We also report the shedding of TGF by patients undergoing irradiation for hormone-refractory prostate cancer.

Experimental Design: TGF levels were determined by ELISA. DU145 xenografts were established on the flanks of athymic nu/nu mice. Expression of phospho-extracellular signal-regulated kinase (ERK)1/2 and phospho-epidermal growth factor receptor (EGFR) and the DNA repair proteins XRCC1 and ERCC1 were determined by Western analyses.

Results: Exposure to ionizing radiation results in a dose-dependent release of TGF . Once released, TGF stimulates EGFR-ERK1/2 signaling in unirradiated cells. Blockade of the EGFR with the tyrphostin AG1478 eliminates the up-regulation XRCC1 and ERCC1 by TGF or irradiation. After irradiation, cells are refractory to additional transactivation of EGFR by additional irradiation for 8 to 12 hours. Irradiation during this refractory period does not increase the expression of XRCC1 or ERCC1. Ligand activation of EGFR is maintained during the refractory period. Irradiation of DU145 xenografts also results in the activation of ERK1/2, release of TGF , and a similar refractory period. Ionizing irradiation also results in the release of TGF for patients undergoing radiation therapy for hormone-refractory prostate cancer.

Conclusions: Irradiation results in a dose-dependent increase in TGF capable of enhancing the growth of DU145 xenografts. TGF is also shed following radiation therapy of patients treated for hormone-refractory prostate cancer. Radiation transactivation of the EGFR produces a radio-refractory period, which lasts for several hours. During this period, additional irradiation fails to induce XRCC1, ERCC1, or additional TGF release.

This article has been cited by other articles:

				W. Li, F. Li, Q. Huang, B. Frederick, S. Bao, and C.-Y. Li Noninvasive Imaging and Quantification of Epidermal Growth Factor Receptor Kinase Activation In vivo Cancer Res., July 1, 2008; 68(13): 4990 - 4997. [Abstract] [Full Text] [PDF]

				Y. Fang, E. Studer, C. Mitchell, S. Grant, W. M. Pandak, P. B. Hylemon, and P. Dent Conjugated Bile Acids Regulate Hepatocyte Glycogen Synthase Activity In Vitro and In Vivo via G{alpha}i Signaling Mol. Pharmacol., April 1, 2007; 71(4): 1122 - 1128. [Abstract] [Full Text] [PDF]

				Q. Qiu, J. Domarkas, R. Banerjee, N. Merayo, F. Brahimi, J. P. McNamee, B. F. Gibbs, and B. J. Jean-Claude The Combi-Targeting Concept: In vitro and In vivo Fragmentation of a Stable Combi-Nitrosourea Engineered to Interact with the Epidermal Growth Factor Receptor while Remaining DNA Reactive Clin. Cancer Res., January 1, 2007; 13(1): 331 - 340. [Abstract] [Full Text] [PDF]

				A. Yacoub, W. Hawkins, D. Hanna, H. Young, M. A. Park, M. Grant, J. D. Roberts, D. T. Curiel, P. B. Fisher, K. Valerie, et al. Human Chorionic Gonadotropin Modulates Prostate Cancer Cell Survival after Irradiation or HMG CoA Reductase Inhibitor Treatment Mol. Pharmacol., January 1, 2007; 71(1): 259 - 275. [Abstract] [Full Text] [PDF]

				A. Yacoub, A. Miller, R. W Caron, L. Qiao, D. A Curiel, P. B Fisher, M. P Hagan, S. Grant, and P. Dent Radiotherapy-induced signal transduction Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S99 - S114. [Abstract] [Full Text] [PDF]

				R. W. Caron, A. Yacoub, X. Zhu, C. Mitchell, S. I. Han, T. Sasazuki, S. Shirasawa, M. P. Hagan, S. Grant, and P. Dent H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent Mol. Cancer Ther., February 1, 2005; 4(2): 243 - 255. [Abstract] [Full Text] [PDF]

				R. W. Caron, A. Yacoub, M. Li, X. Zhu, C. Mitchell, Y. Hong, W. Hawkins, T. Sasazuki, S. Shirasawa, A. P. Kozikowski, et al. Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival Mol. Cancer Ther., February 1, 2005; 4(2): 257 - 270. [Abstract] [Full Text] [PDF]